Vesselon is a pioneering brand that specializes in the development of patentable drug co-formulations. Their innovative approach combines biochemistry and biophysics to create FDA-approved lipid microspheres and self-assembling liposomes. These co-formulations enhance the efficacy of therapeutic drugs by making targeted tissues more receptive.

With over 1,600 preclinical trials supporting their technology, Vesselon's unique approach has shown significant improvements across various indications. However, the pharmaceutical industry hasn't fully utilized this technology due to concerns about patentability, implementation practicality, and regulatory uncertainty. Vesselon has successfully overcome these barriers with a three-part strategy.

They offer patent protection, an FDA-approved drug with a smooth regulatory path, and an in-clinic, 5-minute conjugation process that doesn't require any modification of the therapeutic agent or changes in the pharmaceutical manufacturing process. By supplementing biochemistry with biophysics, Vesselon enhances the biodistribution and efficacy of drugs. Their lipid microspheres and liposomes protect the drug from the body and vice versa, ensuring safe and effective delivery.

The unique TriForm phenomenon observed in Vesselon's platform allows them to extend the lifecycle of virtually any drug. This breakthrough enables drug firms to grow their market share, explore new indications, and protect their portfolio of drugs. Vesselon's technology is based on a proprietary system that encapsulates an active pharmaceutical ingredient in both lipid microspheres and liposomes.

This conjugation is activated using FDA-sanctioned ultrasound settings, which trigger multiple cellular Modes of Action for enhanced drug uptake. One of the remarkable aspects of Vesselon's approach is that it doesn't require any change in traditional pharmaceutical industry practices or modifications to the drug itself. Their lipid drug product has received FDA approval and is considered as safe as saline.

Vesselon's on-site, in-the-vial mixing process revolutionizes drug conjugation by making it more accessible and practical. By encapsulating already marketed drugs, they have also achieved an unusually low-friction, low-risk regulatory path for product lifecycle management. Building on their success in developing enhanced monoclonal antibodies for cancer treatment, Vesselon's platform has the potential to produce an endless stream of proprietary pharmaceuticals.

Their extensive list of drug formulations includes TriForm encapsulations of pembrolizumab, Interleukin-2, bevacizumab, Interferon-γ, and Ad5/3 multi-targeting adenoviruses expressing various drugs. Vesselon's groundbreaking discoveries have led to composition of matter and method patent filings, covering the instant, on-site encapsulation of any active drug in lipid microspheres and self-assembling liposomes. To learn more about Vesselon and their transformative drug formulations, visit their website or contact them directly